natgillin/translations-raw huggingface dataset:
Given the pharmacokinetic interaction between Kaletra and tenofovir (see section 4.5), the results of this study might not be strictly extrapolable when other backbone regimens are used with Kaletra.
Glede na farmakokinetične interakcije med zdravilom Kaletra in tenofovirjem (glejte poglavje 4.5) rezultatov te študije morda ni mogoče strogo ekstrapolirati na uporabo zdravila Kaletra z drugimi osnovnimi shemami.
Fournier Laboratories Ireland Limited, Carrigtwohill Business Park, Anngrove, Carrigtwohill, Co. Cork, Ireland
Fournier Laboratories Ireland Limited, Carrigtwohill Business Park, Anngrove, Carrigtwohill, Co. Cork, Irska
• damage to nerves of the peripheral nervous system;
- poškodbe perifernih živcev;
EU/1/01/172/005 - multipack: 120 (3 packs of 40) film-coated tablets EU/1/01/172/008 - carton of 120 film-coated tablets
EU/1/01/172/005 - multipakiranje: 120 (3 škatle po 40) filmsko obloženih tablet EU/1/01/172/008 - škatla s 120 filmsko obloženimi tabletami
Use in adults
Uporaba pri odraslih
No pattern of birth defects suggestive of a common etiology was seen.
V skupni etiologiji niso opazili vzorca prirojenih napak.
Careful monitoring of the tolerance of these anticancer agents.
Skrbno spremljanje prenašanja teh zdravil proti raku.
The clinical relevance of these preclinical data is unknown, however, the potential cardiac effects of this product in humans cannot be ruled out (see also sections 4.4 and 4.8).
Klinični pomen teh predkliničnih podatkov ni znan, vendar kardialnih učinkov tega zdravila pri človeku ni mogoče izključiti (glejte tudi poglavji 4.4 in 4.8).
In dogs, prominent U waves on the electrocardiogram have been observed associated with prolonged PR interval and bradycardia.
Pri psih so na elektrokardiogramu opažali izrazite zobce U v povezavi s podaljšanim intervalom PR in bradikardijo.
What Kaletra is and what it is used for What you need to know before you or your child takes Kaletra How to take Kaletra
Kaj je zdravilo Kaletra in za kaj ga uporabljamo Kaj morate vedeti, preden boste vi ali vaš otrok vzeli zdravilo Kaletra Kako jemati zdravilo Kaletra
Kaletra is an antiretroviral medicine.
Zdravilo Kaletra je protivirusno zdravilo.
Your doctor will advise on the amount of Kaletra to be taken.
Zdravnik vam bo svetoval, koliko zdravila Kaletra morate vzeti.
The clinical significance of reduced abacavir and zidovudine concentrations is unknown.
Klinični pomen znižane koncentracije abakavirja in zidovudina ni znan.
Oral solution The solution is light yellow to orange.
peroralna raztopina Raztopina je svetlo rumene do oranžne barve.
• It is recommended that HIV-infected women do not breast-feed their infants because there is a possibility that the baby can be infected with HIV through your breast milk.
- Priporočeno je, da s HIV okužene ženske ne dojijo, ker se otrok lahko z materinim mlekom okuži s HIV.
If you are taking Kaletra twice a day
Če jemljete zdravilo Kaletra dvakrat na dan
If Kaletra is co-administered with parenteral midazolam, it should be done in an intensive care unit (ICU) or similar setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation.
Če je zdravilo Kaletra uporabljeno sočasno s parenteralnim midazolamom, je to potrebno izvesti v enoti za intenzivno nego (EIN) ali podobnem okolju, ki omogoča natančen kliničen nadzor in ustrezno medicinsko ukrepanje v primeru depresije dihanja in/ali dolgotrajne sedacije.
Buproprion and its active metabolite, hydroxybupropion:
Buproprion in njegov aktivni presnovek hidroksibupropion:
Unless otherwise stated, studies detailed below have been performed with the recommended dosage of lopinavir/ritonavir (i.e. 400/100 mg twice daily).
Če ni navedeno drugače, so bile spodaj omenjene študije opravljene s priporočenim odmerjanjem lopinavirja/ritonavirja (tj. 400/100 mg dvakrat na dan).
If the benefit is considered to outweigh the risk and Kaletra must be used, reduce the ibrutinib dose to 140 mg and monitor patient closely for toxicity.
Če korist odtehta tveganje in je treba zdravilo Kaletra uporabiti, zmanjšajte odmerek ibrutiniba na 140 mg in pozorno spremljate bolnika za toksičnost.
This effect may be due to induction of bupropion metabolism.
To je morda posledica indukcije presnove bupropiona.
See section 4.4 and section 4.5 for co-administration of sildenafil in patients with erectile dysfunction.
Glejte poglavje 4.4 in poglavje 4.5 za sočasno uporabo sildenafila pri bolnikih z erektilno disfunkcijo.
Diarrhoea, nausea and vomiting may occur at the beginning of the treatment while hypertriglyceridaemia and hypercholesterolemia may occur later.
Driska, slabost in bruhanje se lahko pojavijo v začetku zdravljenja, medtem ko se hipertrigliceridemija in hiperholesterolemija lahko pojavita kasneje.
Contents of the pack and other information What Kaletra contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Kaletra
This may result in lowered plasma concentrations and potential decrease of efficacy of co-administered medicinal products.
To lahko zniža plazemske koncentracije in potencialno zmanjša učinkovitost sočasno uporabljenih zdravil.
AUC and Cmax ↓ ~50%
AUC in Cmax ↓ ~50 %
Outcomes at Week 24: Study P1060 Cohort I
Rezultati v 24. tednu: Študija P1060 Kohorta I
Paediatric dosing guidelines based on body weight* > 6 months to 18 years
Smernice za pediatrično odmerjanje na osnovi telesne mase* > 6 mesecev do 18 let
Resistance to nelfinavir, defined as the presence of the D30N or L90M mutation in protease, was observed in 41/96 (43%) patients.
Odpornost proti nelfinavirju, definirana kot prisotnost D30N ali L90M mutacij v proteazi, je bila opažena pri 41/96 (43 %) bolnikih.
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
A. IZDELOVALEC (IZDELOVALCI), ODGOVOREN ZA SPROŠČANJE SERIJ
For monitoring of blood lipids and glucose, reference is made to established HIV treatment guidelines.
Za nadzor lipidov in glukoze v krvi je treba upoštevati veljavne smernice za zdravljenje okužbe z virusom HIV.
Patients on a low potassium diet should be cautioned.
Bolnike na dieti z malo kalija je treba na to opozoriti.
Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to combination antiretroviral therapy (CART).
Opisani so bili primeri osteonekroze, še zlasti pri bolnikih s splošno znanimi dejavniki tveganja, napredovalo boleznijo HIV ali dolgotrajno izpostavljenostjo kombiniranemu protiretrovirusnemu zdravljenju (CART).
Particular risk of toxicity in relation to the amount of alcohol and propylene glycol contained in Kaletra oral solution
Posebno tveganje toksičnosti glede na količino alkohola in propilenglikola v zdravilu Kaletra peroralna raztopina
Therefore, this co-administration should be avoided unless judged strictly necessary.
Zato se je takšni sočasni uporabi treba izogniti, če ni res nujna.
Integrase inhibitor Raltegravir
Zaviralci integraze Raltegravir
• severe or life threatening skin rashes and blisters (Stevens-Johnson syndrome and erythema multiforme).
• hudi ali življenje-ogrožujoči izpuščaji in mehurji (Stevens-Johnsonov sindrom in multiformni eritem).
A limited increase in total lopinavir concentrations of approximately 30% has been observed which is not expected to be of clinical relevance (see section 4.2).
Opazili so omejeno zvišanje koncentracij lopinavirja za približno 30 %, kar ni pričakovati, da bi bilo klinično pomembno (glejte poglavje 4.2).
Pharmaco-therapeutic group: antivirals for systemic use, antivirals for treatment of HIV infections, combinations, ATC code: J05AR10
5.1 Farmakodinamične lastnosti Farmakoterapevtska skupina: protivirusne učinkovine za sistemsko uporabo, protivirusne učinkovine za zdravljenje okužb s HIV, kombinacije, oznaka ATC: J05AR10
Based on the current data available, Kaletra should not be administered once daily in paediatric patients (see section 5.1).
Na podlagi dosedanjih podatkov, ki so na razpolago, se zdravila Kaletra ne sme odmerjati enkrat na dan pri pediatričnih bolnikih (glejte poglavje 5.1).
Concomitant use of Kaletra with rilpivirine causes an increase in the plasma concentrations of rilpivirine, but no dose adjustment is required.
Sočasna uporaba zdravila Kaletra z rilpivirinom povzroči zvišanje plazemskih koncentracij rilpivirina, vendar prilagoditev odmerka ni potrebna.
If more convenient for patients, the Kaletra 200/50 mg tablets may also be considered alone or in combination with the Kaletra 100/25 mg tablet to achieve the recommended dose.
Če je za bolnika bolj primerno, pride v poštev tudi uporaba tablet zdravila Kaletra 200/50 mg samih ali v kombinaciji s tabletami zdravila Kaletra 100/25 mg, da bi dosegli priporočeni odmerek.
Mutations L33F, I50V and V32I combined with I47V/A were also observed.
Opažali so tudi mutacije L33F, I50V in V32I v kombinaciji z I47V/A.
These changes were reversible with withdrawal of the active substance and were absent in mice and dogs.
Te spremembe so bile po odtegnitvi zdravilne učinkovine reverzibilne, pri miših in psih pa jih ni bilo.
It is advised to write the date of removal from the refrigerator on the package.
Na ovojnino je priporočljivo zapisati datum, ko ste zdravilo vzeli iz hladilnika.
Haemophiliac patients should therefore be made aware of the possibility of increased bleeding.
Bolnike s hemofilijo je zato treba seznaniti z možnostjo, da se zveča nagnjenost h krvavitvam.
You should see the ‘ml' marking aligned to the top of the collar of the barrel.
Oznako z ‘ml' morate videti poravnano z vrhom obroča cevi.
Antibiotic
Antibiotik
The choice of Kaletra to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients (see sections 4.4 and 5.1).
Izbira zdravila Kaletra za zdravljenje s HIV-1 okuženih in z zaviralci proteaz izkušenih bolnikov mora temeljiti na individualnem preizkusu odpornosti virusa in anamnezi bolnikovega zdravljenja (glejte poglavji 4.4 in 5.1).
No human data on the effect of lopinavir/ritonavir on fertility are available.
Ni razpoložljivih podatkov o vplivu lopinavirja/ritonavirja na plodnost pri ljudeh.
Most tyrosine kinase inhibitors such as dasatinib and nilotinib, vincristine, vinblastine
Večina zaviralcev tirozin kinaz, kot so dasatinib in nilotinib, vinkristin, vinblastin
Dose adjustment has not been evaluated in clinical practice.
Prilagoditev odmerka ni ovrednotena v klinični praksi.
Healthcare professionals should be aware that Kaletra oral solution is highly concentrated and contains 42.4% alcohol (v/v) and 15.3% propylene glycol (w/v).
Zdravstveni delavci morajo upoštevati, da je zdravilo Kaletra peroralna raztopina zelo koncentrirano in vsebuje 42,4 % alkohola (v/v) in 15,3 % propilenglikola (m/v).
Long-term carcinogenicity studies of lopinavir/ritonavir in mice revealed a nongenotoxic, mitogenic induction of liver tumours, generally considered to have little relevance to human risk.
Dolgotrajne študije lopinavirja/ritonavirja pri miših so pokazale negenotoksično, mitogeno indukcijo jetrnih tumorjev, za katero na splošno velja, da je malo pomembna za tveganje pri človeku.
Patients were administered at least two nucleoside/nucleotide reverse transcriptase inhibitors selected by the investigator.
Bolniki so dobivali vsaj dva zaviralca nukleozidne/nukleotidne reverzne transkriptaze, ki ju je izbral raziskovalec.
Greater effects may be expected when fluticasone propionate is inhaled.
Med vdihavanjem flutikazonpropionata je mogoče pričakovati večje učinke.
Thyroid-stimulating hormone (TSH) should be monitored in patients treated with levothyroxine at least the first month after starting and/or ending lopinavir/ritonavir treatment.
Pri bolnikih, ki se zdravijo z levotiroksinom, je treba spremljati ščitnico stimulirajoči hormon (TSH) vsaj prvi mesec po začetku in/ali koncu zdravljenja z lopinavirjem/ritonavirjem.
When you travel or need to stay in the hospital make sure you will have enough Kaletra to last until you can get a new supply.
Če greste na potovanje ali v bolnišnico, imejte s seboj vedno toliko zdravila Kaletra, da vam bo zadostovalo, dokler ne dobite nove zaloge.
If indicated, elimination of unabsorbed active substance is to be achieved by emesis or gastric lavage.
Če je indicirano, je odstranitev neabsorbirane zdravilne učinkovine mogoče doseči z bruhanjem ali izpiranjem želodca.
There are limited pharmacokinetic data in children below 2 years of age.
Pediatrični bolniki Farmakokinetični podatki pri otrocih do 2. leta starosti so omejeni.
Other medicines and Kaletra);
Druga zdravila in zdravilo Kaletra);
Adequate exposure to lopinavir/ritonavir may be achieved when a higher dose of Kaletra is used but this is associated with a higher risk of liver and gastrointestinal toxicity.
Zadostno izpostavljenost kombinaciji lopinavir/ritonavir se lahko doseže z uporabo višjega odmerka zdravila Kaletra, vendar je to povezano z večjim tveganjem za jetrno in gastrointestinalno toksičnost.
Caution is warranted and therapeutic drug concentration monitoring is recommended when available.
Potrebna je previdnost in priporočljivo je nadziranje terapevtske koncentracije zdravila, če je to mogoče.
The pharmacokinetic properties of lopinavir co-administered with ritonavir have been evaluated in healthy adult volunteers and in HIV-infected patients; no substantial differences were observed between the two groups.
Farmakokinetične lastnosti lopinavirja, uporabljenega hkrati z ritonavirjem, so ocenili pri zdravih odraslih prostovoljcih in pri bolnikih, okuženih s HIV; med skupinama niso opazili bistvenih razlik.
• alfuzosin (used in men to treat symptoms of an enlarged prostate (benign prostatic hyperplasia (BPH));
- alfuzosin (uporablja se pri moških za zdravljenje simptomov povečane prostate (benigne hiperplazije prostate (BHP));
Genotypic correlates of reduced phenotypic susceptibility to lopinavir in viruses selected by other protease inhibitors.
Genotipski korelati manjše fenotipske občutljivosti za lopinavir pri virusih, selekcioniranih z drugimi zaviralci proteaz.
Tell your doctor if you or your child have/had
Povejte svojemu zdravniku, če vi ali vaš otrok imate ali ste imeli
Kaletra contains glycerol which is harmful in high doses.
Zdravilo Kaletra vsebuje glicerol, ki je v velikih odmerkih škodljiv.
(inhibition of CYP3A/efflux transporters)
(zavrtje CYP3A/efluksnih transporterjev)
If you are not sure how to use the oral dosing syringe ask your doctor, pharmacist or nurse.
Če niste prepričani, kako uporabljati brizgo za peroralno dajanje, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
The 19 isolates demonstrated a 4.3-fold increase in IC50 compared to baseline isolates (from 6.2- to 43-fold, compared to wild-type virus).
Pri 19 izolatih so ugotovili 4,3-kratno povečanje IC50 v primerjavi z izhodiščnimi izolati (od 6,2- do 43-kratno v primerjavi z divjim tipom virusa).
Particular caution must be used when prescribing Kaletra and medicinal products known to induce QT interval prolongation such as: chlorpheniramine, quinidine, erythromycin, clarithromycin.
Posebna previdnost je potrebna pri predpisovanju zdravila Kaletra in zdravil, ki podaljšujejo interval QT; takšna so npr. klorfeniramin, kinidin, eritromicin, klaritromicin.
The absolute bioavailability of lopinavir co-formulated with ritonavir in humans has not been established.
Absolutna biološka uporabnost lopinavirja, koformuliranega z ritonavirjem, pri ljudeh ni ugotovljena.
Carcinogenicity studies in rats revealed no tumourigenic findings.
Raziskave kancerogenosti pri podganah niso pokazale tumorigenosti.
If treatment with an HMG-CoA reductase inhibitor is indicated,
Če je indicirano zdravljenje z zaviralcem reduktaze HMG-CoA,
As compared to the BID regimen, the once-daily dosing is associated with a reduction in the Cmin/Ctrough values of approximately 50%.
V primerjavi s shemo dvakrat na dan je bilo odmerjanje enkrat na dan povezano z zmanjšanjem vrednosti Cmin/Ctrough za približno 50 %.
Do not shake the bottle - this is because air bubbles can form which will affect how well you can measure the dose.
Plastenke ne stresajte, ker lahko nastanejo zračni mehurčki, ki bodo vplivali na natančnost pri odmerjanju.
Patients with pre-existing liver dysfunction including chronic hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Pri bolnikih z obstoječo disfunkcijo jeter, vključno s kroničnim hepatitisom, se med kombiniranim protiretrovirusnim zdravljenjem pogosteje pojavljajo nepravilnosti v delovanju jeter, zato jih je treba nadzirati v skladu s standardno prakso.
The systemic exposure to lopinavir/ritonavir at the maternal and developmental toxic dosages was lower than the intended therapeutic exposure in humans.
Sistemska izpostavljenost lopinavirju/ritonavirju je bila ob maternalnih in razvojno toksičnih odmerkih manjša, kot je predvidena terapevtska izpostavljenost pri človeku.
Like all medicines, Kaletra can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Kaletra neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Can cause headache and stomach upset and diarrhoea.
Povzroči lahko glavobol, želodčne težave in drisko.
• Do not stop or change the daily dose of Kaletra without first consulting with your doctor.
- Dnevnega odmerka zdravila Kaletra ne opuščajte in ne spreminjajte, ne da bi se prej posvetovali z zdravnikom.
Lopinavir is an inhibitor of the HIV-1 and HIV-2 proteases.
Lopinavir je zaviralec proteaz HIV-1 in
‘ml' mark
Oznaka z ‘ml'
Initially, bosentan Cmin: ↑ by approximately 48-fold.
Uvodoma Cmin bosentana: ↑ za približno 48-krat.
• an abnormality in your electrocardiogram (ECG) called atrioventricular block;
- izpadanje las; - nenormalnost v elektrokardiogramu (EKG), ki se imenuje atrioventrikularni blok;
Patients with advanced HIV disease may be at risk of elevated triglycerides and pancreatitis.
Bolnike z napredovalo boleznijo HIV utegneta ogrožati zvišanje trigliceridov in pankreatitis.
In case of co-administration of Kaletra with contraceptives containing ethinyl oestradiol (whatever the contraceptive formulation e.g. oral or patch), additional methods of contraception must be used.
Kaletra s kontraceptivi, ki vsebujejo etinilestradiol (ne glede na formulacijo kontraceptiva, npr. peroralni ali obliž), je treba uporabiti dodatne načine kontracepcijske zaščite.
Volume of oral solution twice daily taken with food (80 mg lopinavir/20 mg ritonavir per ml)**
Volumen peroralne raztopine dvakrat na dan skupaj s hrano (80 mg lopinavirja/20 mg ritonavirja na ml)**
Study P1060 was a randomised controlled trial of nevirapine versus lopinavir/ritonavir-based therapy in subjects 2 to 36 months of age infected with HIV-1 who had (Cohort I) and had not (Cohort II) been exposed to nevirapine during pregnancy for prevention of mother-to-child transmission.
Študija P1060 je bilo randomizirano, kontrolirano preskušanje zdravljenja z nevirapinom v primerjavi z zdravljenjem s kombinacijo lopinavirja/ritonavirja pri preiskovancih, starih od 2 do 36 mesecev, okuženih z virusom HIV-1, ki so bili izpostavljeni (kohorta I) in ki niso bili izpostavljeni (kohorta II) nevirapinu med nosečnostjo, za preprečevanje prenosa okužbe z mame na otroka.
Pancreatitis should be considered if clinical symptoms (nausea, vomiting, abdominal pain) or abnormalities in laboratory values (such as increased serum lipase or amylase values) suggestive of pancreatitis should occur.
Na pankreatitis je treba pomisliti, če se pojavijo klinični simptomi (navzeja, bruhanje, bolečine v trebuhu) ali nenormalne laboratorijske vrednosti (npr. zvišanje serumske lipaze ali amilaze), ki nakazujejo pankreatitis.
Very common: may affect more than 1 in 10 people
Zelo pogosti: pojavijo se pri več kot 1 od 10 bolnikov
300/75 mg/m2 (corresponding to 3.75 ml/m2)
300/75 mg/m2 (kar ustreza 3,75 ml/m2)
• breakdown of muscle fibres resulting in the release of muscle fibre contents (myoglobin) into the bloodstream;
- razpad mišičnih vlaken, ki privede do sproščanja vsebine mišičnih vlaken (mioglobina) v krvni obtok;
Contraindicated when used for the treatment of pulmonary arterial hypertension (PAH) only.
Kontraindiciran je samo v primeru uporabe za zdravljenje pljučne arterijske hipertenzije (PAH).
Cardiac events have been reported with Kaletra in preclinical studies; therefore, the potential cardiac effects of Kaletra cannot be currently ruled out (see sections 4.8 and 5.3).
V predkliničnih raziskavah z zdravilom Kaletra so poročali o kardialnih incidentih, zato možnih učinkov zdravila Kaletra na srce trenutno ni mogoče izključiti (glejte poglavji 4.8 in 5.3).
Due to induction of lamotrigine glucuronidation
Zaradi indukcije glukuronidacije lamotrigina.
Increased plasma concentrations of alfuzosin which may lead to severe hypotension.
Večja koncentracija alfuzosina v plazmi, ki lahko povzroči hudo hipotenzijo.
4 tablets (400/100 mg) 5 tablets (500/125 mg)
4 tablete (400/100 mg) 5 tablet (500/125 mg)
Overall, the in vitro characterisation of phenotypic cross-resistance between lopinavir and other protease inhibitors suggest that decreased susceptibility to lopinavir correlated closely with decreased susceptibility to ritonavir and indinavir, but did not correlate closely with decreased susceptibility to amprenavir, saquinavir, and nelfinavir.
V celoti gledano karakterizacija fenotipske navzkrižne odpornosti med lopinavirjem in drugimi zaviralci proteaz in vitro nakazuje, da manjša občutljivosti za lopinavir tesno korelira z manjšo občutljivostjo za ritonavir in indinavir, ne korelira pa tesno z manjšo občutljivostjo za amprenavir, sakvinavir in nelfinavir.
Co-administration of Kaletra and medicinal products primarily metabolised by CYP3A may result in increased plasma concentrations of the other medicinal product, which could increase or prolong its therapeutic and adverse reactions.
Sočasna uporaba zdravila Kaletra in zdravil, ki se primarno presnavljajo s CYP3A, lahko zveča koncentracijo drugega zdravila v plazmi, to pa lahko zveča ali podaljša njegove terapevtske in neželene učinke.
Both treatment arms included zidovudine 180 mg/m2 every 12 hours and lamivudine 4 mg/kg every 12 hours.
Zdravljenje v obeh skupinah je vključevalo tudi zidovudin 180 mg/m2 vsakih 12 ur in lamivudin 4 mg/kg vsakih 12 ur.
16/4 mg/kg (corresponding to 0.2 ml/kg)
16/4 mg/kg (kar ustreza 0,2 ml/kg)
Besides propylene glycol as described above, Kaletra oral solution contains alcohol (42% v/v) which is potentially harmful for those suffering from liver disease, alcoholism, epilepsy, brain injury or disease as well as for pregnant women and children.
Poleg propilenglikola, kot je opisano zgoraj, vsebuje peroralna raztopina zdravila Kaletra alkohol (42 % v/v), ki lahko škoduje bolnikom z boleznijo jeter, alkoholizmom, epilepsijo, možgansko okvaro ali boleznijo ter nosečnicam in otrokom.
Based on known metabolic profiles, clinically significant interactions are not expected between Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Na temelju znanih presnovnih značilnosti ni pričakovati klinično pomembnega medsebojnega delovanja zdravila Kaletra in dapsona, trimetoprima/sulfametoksazola, azitromicina ali flukonazola.
Not known Stevens-Johnson syndrome, erythema multiforme
Stevens-Johnsonov sindrom, multiformni eritem
C24: ↑ 20.70-fold
C24: ↑ 20,70-krat
High density polyethylene (HDPE) bottles closed with propylene caps.
Plastenke iz polietilena velike gostote (HDPE), zaprte s propilensko zaporko.
Appropriate laboratory testing should be conducted prior to initiating therapy with lopinavir/ritonavir and close monitoring should be performed during treatment.
Pred začetkom zdravljenja z lopinavirjem/ritonavirjem je potrebno ustrezno laboratorijsko testiranje, med zdravljenjem pa strogo nadzorovanje.
The dose should be administered using a calibrated 2 ml or 5 ml oral dosing syringe best corresponding to the volume prescribed.
Za dajanje odmerka je treba uporabiti kalibrirano 2 ml ali 5 ml brizgo za peroralno dajanje, ki najbolj ustreza predpisanemu volumnu.